Marinus Pharmaceuticals (MRNS) : 3 analysts are covering Marinus Pharmaceuticals (MRNS) and their average rating on the stock is 2.33, which is read as a Buy. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Marinus Pharmaceuticals (MRNS) : 2 Wall Street analysts covering Marinus Pharmaceuticals (MRNS) believe that the average level the stock could reach for the short term is $2.5. The maximum price target given is $3 and the minimum target for short term is around $2, hence the standard deviation is calculated at $0.71.
For the current week, the company shares have a recommendation consensus of Buy. Also, Jefferies maintains its view on Marinus Pharmaceuticals (NASDAQ:MRNS) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Jefferies raises the price target from $2.5 per share to $3 per share on Marinus Pharmaceuticals . The rating by the firm was issued on August 10, 2016.
Marinus Pharmaceuticals (NASDAQ:MRNS): stock was range-bound between the intraday low of $1.6 and the intraday high of $1.79 after having opened at $1.69 on Wednesdays session. The stock finally closed in the red at $1.69, a loss of -1.16%. The stock remained in the red for the whole trading day. The total traded volume was 391,043 shares. The stock failed to cross $1.79 in Wednesdays trading. The stocks closing price on Thursday was $1.73.
Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company focuses on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, which is an endogenous neurosteriod known for its anticonvulsive and antianxiety activity. Ganaxolone was rationally designed to unlock the potential for chronic neurosteroid therapy through modulation of the GABAA receptor. The Companys indication for ganaxolone is as an adjunctive, or add-on, therapy for the treatment of partial, also known as focal, onset seizures in adults with epilepsy. Phase III randomized multinational clinical trial by utilizing the Companys oral capsules. The Company has completed a Phase II clinical trial in 147 patients with focal onset seizures.